Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

被引：92

作者：

Lou, Yan ^{[1
]}

Han, Xiaochun ^{[1
]}

Kuglstatter, Andreas ^{[1
]}

Kondru, Rama K. ^{[1
]}

Sweeney, Zachary K. ^{[1
]}

Soth, Michael ^{[1
]}

McIntosh, Joel ^{[1
]}

Litman, Renee ^{[1
]}

Suh, Judy ^{[1
]}

Kocer, Buelent ^{[1
]}

Davis, Dana ^{[1
]}

Park, Jaehyeon ^{[1
]}

Frauchiger, Sandra ^{[1
]}

Dewdney, Nolan ^{[1
]}

Zecic, Hasim ^{[1
]}

Taygerly, Joshua P. ^{[1
]}

Sarma, Keshab ^{[1
]}

Hong, Junbae ^{[1
]}

Hill, Ronald J. ^{[1
]}

Gabriel, Tobias ^{[1
]}

Goldstein, David M. ^{[1
]}

Owens, Timothy D. ^{[1
]}

机构：

[1] Hoffmann La Roche Inc, Discovery Chem, Small Mol Res, PRED, Palo Alto, CA 94304 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 01期

关键词：

B-CELL; JAK INHIBITOR; DISCOVERY; DISEASES;

D O I：

10.1021/jm500305p

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) ( J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

引用

页码：512 / 516

页数：5

共 50 条

[1] RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
Xu, Daigen
Kim, Yong
Postelnek, Jennifer
Minh Diem Vu
Hu, Dong-Qing
Liao, Cheng
Bradshaw, Mike
Hsu, Jonathan
Zhang, Jun
Pashine, Achal
Srinivasan, Dinesh
Woods, John
Levin, Anita
O'Mahony, Alison
Owens, Timothy D.
Lou, Yan
Hill, Ronald J.
Narula, Satwant
DeMartino, Julie
Fine, Jay S.
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (01): : 90 - 103
[2] Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
Dong, Xing-Duo
Zhang, Meng
Ma, Xiubin
Wang, Jing-Quan
Lei, Zi-Ning
Teng, Qiu-Xu
Li, Yi-Dong
Lin, Lusheng
Feng, Weiguo
Chen, Zhe-Sheng
[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
[3] Suppression of Glomerulonephritis in NZB/W F1 Mice by a Selective Inhibitor of Bruton's Tyrosine Kinase (RN486)
Mina-Osorio, Paola
LaStant, Jacob
Keirstead, Natalie
Whittard, Toni
Stefanova, Stella
Patel, Alka
Postelnek, Jennifer
Woods, John
Min, Soo
Kim, Yong
Demartino, Julie
Narula, Satwant
Xu, Daigen
[J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S746 - S746
[4] Suppression of Glomerulonephritis in Lupus-Prone NZB x NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase
Mina-Osorio, Paola
LaStant, Jacob
Keirstead, Natalie
Whittard, Toni
Ayala, Julia
Stefanova, Stella
Garrido, Rosario
Dimaano, Nena
Hilton, Holly
Giron, Mario
Lau, Kai-Yeung
Hang, Julie
Postelnek, Jennifer
Kim, Yong
Min, Soo
Patel, Alka
Woods, John
Ramanujam, Meera
DeMartino, Julie
Narula, Satwant
Xu, Daigen
[J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (09): : 2380 - 2391
[5] A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation
Lopez-Tapia, Francisco
Lou, Yan
Brotherton-Pleiss, Christine
Kuglstatter, Andreas
So, Sung-Sau
Kondru, Rama
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (09) : 1074 - 1078
[6] RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells
Dong, Xing-Duo
Lu, Qisi
Li, Yi-Dong
Cai, Chao-Yun
Teng, Qiu-Xu
Lei, Zi-Ning
Wei, Zeng-Hui
Yin, Fan
Zeng, Leli
Chen, Zhe-Sheng
[J]. JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (03) : 288 - 298
[7] RN486, a Bruton's tyrosine kinase inhibitor, reverses multidrug resistance in ABCG2-overexpressing cancer cells
Dong, Xing-Duo
Lu, Qisi
Li, Yi-Dong
Teng, Qiu-Xu
Lei, Zi-Ning
Chen, Zhe-Sheng
[J]. CANCER RESEARCH, 2023, 83 (07)
[8] TAS5315, a Novel Bruton's Tyrosine Kinase (BTK) Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis
Hosoi, Fumihito
Yoshiga, Youhei
Iguchi, Satoru
Kaneko, Ryuusuke
Nakachi, Yoshinori
Akasaka, Daichi
Yonekura, Kazuhiko
Utsugi, Teruhiro
Sasaki, Eiji
Iwasawa, Yoshikazu
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[9] Structure-based design of small molecules that inhibit Bruton's tyrosine kinase (BTK) activity and function.
Mahajan, S
Ghosh, S
Mao, C
Sudbeck, E
Zheng, Y
Uckun, FM
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) : S120 - S120
[10] Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
Caldwell, Richard D.
Qiu, Hui
Askew, Ben C.
Bender, Andrew T.
Brugger, Nadia
Camps, Montserrat
Dhanabal, Mohanraj
Dutt, Vikram
Eichhorn, Thomas
Gardberg, Anna S.
Goutopoulos, Andreas
Grenningloh, Roland
Head, Jared
Healey, Brian
Hodous, Brian L.
Huck, Bayard R.
Johnson, Theresa L.
Jones, Christopher
Jones, Reinaldo C.
Mochalkin, Igor
Morandi, Federica
Ngan Nguyen
Meyring, Michael
Potnick, Justin R.
Santos, Dusica Cvetinovic
Schmidt, Ralf
Sherer, Brian
Shutes, Adam
Urbahns, Klaus
Follis, Ariele Viacava
Wegener, Ansgar A.
Zimmerli, Simone C.
Liu-Bujalski, Lesley
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 7643 - 7655

← 1 2 3 4 5 →